Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03136198
Other study ID # 1R34HL136986-01
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 10, 2017
Est. completion date June 20, 2019

Study information

Verified date June 2024
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Nearly 80% of acute heart failure (AHF) patients admitted to the hospital are initially treated in the emergency department (ED). Once admitted, within 30 days post-discharge, 27% of patients are re-hospitalized or die. Attempts to improve outcomes with novel therapies have all failed. The evidence for existing AHF therapies are poor: No currently used AHF treatment is known to improve outcomes. ED treatment is largely the same today as 40 years ago. Congestion, such as difficulty breathing, weight gain, and leg swelling, is the primary reason why patients present to the hospital for AHF. Treating congestion is the cornerstone of AHF management. Yet half of all AHF patients leave the hospital inadequately decongested. The investigators propose a novel approach to aggressively decongest patients in the ED setting: lung ultrasound guided, protocol driven, AHF management. LUS B-lines are a measure of extra-vascular lung water (EVLW). In the setting of AHF, LUS B-lines are a measure of congestion. This simple, easily learned technique has excellent reliability and reproducibility. The investigators hypothesize that a strategy-of-care will outperform usual care. At the present time, usual care is largely empirical. This study will improve the evidence base for ED AHF management. This proposed pilot study, if successful, will lead to an outcome trial examining whether an ED AHF strategy-of-care increases days alive and out of the hospital for patients.


Description:

The primary goal of the BLUSHED AHF pilot trial is to determine whether an early lung ultrasound (LUS) guided, protocol-driven ED AHF strategy-of-care leads to more rapid and sustained resolution of congestion, as measured by LUS B-lines. If the investigators are able to demonstrate this necessary and sufficient information - targeted strategy-of-care is more effective than usual care - they will apply for a follow on study to achieve the following aim. Aim 1: To demonstrate the effectiveness of a targeted decongestion strategy - LUS guided, protocol-driven ED AHF management - will result in improved 30-day outcomes vs. usual care. This aim will be tested using a randomized, controlled, unblinded, pragmatic, multi-center, simple trial design. The pilot trial may determine that ED management alone is insufficient to impact the outcome. Thus, the investigators may need to modify their subsequent trial design to include targeted therapy throughout hospitalization. However, the pilot study will demonstrate whether targeted therapy effectively reduces B-lines. PUBLIC HEALTH IMPACT Over one million hospitalizations for AHF occur every year in the US. Within 30 days after hospitalization, over 25% of AHF patients will be dead or re-hospitalized.4 Up to 67% of patients will be re-hospitalized and 36% will be dead by one year. For patients aged 65 years and older, AHF is the most common and most expensive reason for hospitalization. Despite major reductions in morbidity and mortality for chronic HF, considerably less progress has been seen in AHF. Congestion is the primary reason why AHF patients present to the ED seeking medical care. Congestion is manifest by signs and symptoms of heart failure (HF); dyspnea, orthopnea, edema, and weight gain. Yet, how to best assess, grade, and manage congestion is not well established. Freedom from congestion is associated with improved outcomes; Yet many patients leave the hospital inadequately decongested. The absence of robust, reliable methods to assess congestion is a primary reason why it is not well-assessed. A recent consensus statement published in 2010 highlights this fact: "…no method to assess congestion…has been validated." The investigators would argue many ED AHF patients are poorly assessed prior to treatment. In addition, they are poorly re-assessed prior to hospitalization to gauge the success or failure of initial management. While physical exam is currently the cornerstone of congestion assessment, it lacks sensitivity and inter-rater reliability. The investigators challenge the current paradigm of relying on insensitive methods of congestion to guide therapy. Furthermore, they argue the lack of a robust evidence base for ED management of congestion contributes to poor outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date June 20, 2019
Est. primary completion date March 20, 2019
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Age = 21 years - Presents with shortness of breath at rest or with minimal exertion - Clinical diagnosis of AHF and presence of > 15 total bilateral B-lines distributed in at least 4 zones on initial LUS - Hx of chronic HF and any one of the following: - Chest radiograph consistent with AHF - Jugular venous distension - Pulmonary rales on auscultation - Lower extremity edema Exclusion Criteria: - Chronic renal dysfunction, including end-stage renal disease (ESRD) or estimated glomerular filtration rate (eGFR) < 45ml//min/1.73m2. - Shock of any kind. Any requirement for vasopressors or inotropes. - Systolic blood pressure (SBP) < 100 or >175 mmHg - Need for immediate intubation - Acute Coronary Syndrome- Presentation consistent with myocardial ischemia AND either new ST-segment elevation/depression - Fever >101.5 ºF or chest radiograph or clinical picture of pneumonia - End stage HF: transplant list, ventricular assist device - Anemia requiring transfusion - Known interstitial lung disease - Suspected acute lung injury or acute respiratory distress syndrome (ARDS) - Pregnant or recently pregnant within the last 6 months

Study Design


Intervention

Other:
LUS-guided strategy-of-care
For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to = 15 or 6 hours of care has been delivered, whichever comes first. Treatment protocol: IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive. Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV) Reassessment every 2 hours
Usual Care
Patients will receive usual AHF care
Drug:
Intravenous Loop Diuretic
IV loop diuretic
Vasodilator
IV, topical, or SL Vasodilator
Device:
Non invasive Ventilation (NIV)
Face, mouth, or nasal mask applied to provide positive pressure ventilation

Locations

Country Name City State
United States Case Western Reserve University Cleveland Ohio
United States Detroit Receiving Hospital Detroit Michigan
United States INOVA Health System Fairfax Virginia
United States Eskenazi Health Indianapolis Indiana
United States IU Health Methodist Hospital Indianapolis Indiana
United States Vanderbilt University Nashville Tennessee

Sponsors (5)

Lead Sponsor Collaborator
Indiana University Case Western Reserve University, Inova Fairfax Hospital, Vanderbilt University, Wayne State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Total Days Alive and Out Of Hospital (DAOOH) Total days alive and out of hospital through 30 and 90 days post-discharge Up through 90 days, with specific reporting of events through 30 and 90 days
Other Association of B-lines at Discharge and 30-day / 90-day Outcomes Up through 90 days, with specific reporting of events through 30 and 90 days
Other Change in Biomarkers From Presentation to Pre-discharge From admission to pre-discharge from the hospital, on average 5 to 7 days.
Other Time to Reach B-lines <15 Throughout hospitalization, on average 5-7 days
Other B Lines < 15 at 24 Hours and at Discharge Through the first 24 hours and then prior to discharge, on average 5-7 days after admission
Other Composite of 30-day and 90-day All-cause Mortality, Cardiovascular (CV) Re-hospitalizations, and CV Emergency Department (ED) Revisits. CV endpoints are defined according to the 2014 American College of Cardiology/American Heart Association (ACC/AHA) Key Data Elements and Definitions for Cardiovascular Endpoint Events. Up through 90 days, with specific reporting of events through 30 and 90 days
Other All Cause Readmissions, All Cause ED Re-visits 30- day and 90-day Up through 90 days, with specific reporting of events through 30 and 90 days
Other Number of Participants With Physical Exam Findings of Heart Failure When Discharge is Compared to Baseline Physical exam includes body weight, peripheral edema, jugular venous distention, pulmonary and cardiac auscultation From admission throughout hospitalization, usually 5-7 days.
Other Count of Pharmacologic Therapies the Patient Received in the ED This is a description of which pharmacologic therapies the patient has received. From admission throughout hospitalization, usually 5-7 days.
Other Count of Pharmacologic and Device Therapies the Patient Received During Hospitalization This is a description of which pharmacologic and device therapies the patient has received. From admission throughout hospitalization, usually 5-7 days.
Other Comparison of LUS Interpretation Within and Between Trained Investigators as Well as the Core Lab Calculation of intra and inter-agreement between investigators and also the Core Lab to determine the reproducibility of LUS From admission throughout hospitalization, usually 5-7 days.
Other Association of Baseline, Discharge, and Change With 30 and 90 Day Outcomes Up through 90 days, with specific reporting of events through 30 and 90 days
Primary Number of Participants With B-lines = 15 at the Conclusion of ED AHF Management B-lines = 15 at the conclusion of ED AHF management or maximum of 6 hours after enrollment, whichever comes first. During the ED phase of management, usually no more than 6 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy